# Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

> **NCT02248207** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1293 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Pramipexole

## Key facts

- **NCT ID:** NCT02248207
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-11
- **Final completion:** —
- **Target enrollment:** 1293 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248207, "Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02248207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*